# UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

> **NCT00734877** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Arkansas** · enrollment: 382 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** M-VTD-PACE
- **DRUG:** TT3-LITE Regimen (L-TT3)

## Key facts

- **NCT ID:** NCT00734877
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2008-07
- **Primary completion:** 2026-09
- **Final completion:** 2027-09
- **Target enrollment:** 382 (ACTUAL)
- **Last updated:** 2025-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00734877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00734877, "UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00734877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*